Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin 4 induced gene 1 protein (IL4I1) is a secreted L-amino acid oxidase primarily expressed by antigen-presenting cells. It catalyzes the oxidative deamination of L-amino acids, producing hydrogen peroxide, ammonia, and keto acids. IL4I1 acts as a metabolic immune checkpoint protein, inhibiting effector T cell proliferation, promoting regulatory T cell differentiation, and enhancing M2 macrophage polarization. It plays roles in cancer, cardiovascular disease, and autoimmunity.
Inhibits effector T cell proliferation, promotes regulatory T cell differentiation, enhances M2 macrophage polarization, suppresses CD8+ T-cell cytotoxicity, downregulates CD3 chain expression on the T-cell receptor complex
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin 4 induced gene 1 protein (IL4I1).